Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
ABDM-compliant platform aims to reduce data duplication, improve interoperability, and streamline healthcare delivery through a unified digital interface
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
The company now offers HerCheck NIPT and a new range of specialty genomic tests
Subscribe To Our Newsletter & Stay Updated